Literature DB >> 16373617

High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention.

Ryuichi Kato, Yukihiko Momiyama, Reiko Ohmori, Nobukiyo Tanaka, Hiroaki Taniguchi, Koh Arakawa, Masatoshi Kusuhara, Haruo Nakamura, Fumitaka Ohsuzu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16373617     DOI： 10.1161/01.ATV.0000194157.26665.e6

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  8 in total

1.  Plasmatic osteopontin and vascular access dysfunction in hemodialysis patients: a cross-sectional, case-control study (The OSMOSIS Study).

Authors:  Julie Contenti; Matthieu Durand; Sandor Vido; Serge Declemy; Juliette Raffort; Joseph Carboni; Sophie Bonnet; Christophe Koelsch; Réda Hassen-Khodja; Philippe Gual; Nathalie M Mazure; Nirvana Sadaghianloo
Journal:  J Nephrol       Date:  2021-09-01       Impact factor: 3.902

2.  Nuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetes-induced hyperglycemia.

Authors:  Lisa M Nilsson-Berglund; Anna V Zetterqvist; Jenny Nilsson-Ohman; Mikael Sigvardsson; Laura V González Bosc; Maj-Lis Smith; Albert Salehi; Elisabet Agardh; Gunilla Nordin Fredrikson; Carl-David Agardh; Jan Nilsson; Brian R Wamhoff; Anna Hultgårdh-Nilsson; Maria F Gomez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-12-03       Impact factor: 8.311

3.  Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis.

Authors:  Laura Bazzichi; Lorenzo Ghiadoni; Alessandra Rossi; Melania Bernardini; Mario Lanza; Francesca De Feo; Camillo Giacomelli; Ilaria Mencaroni; Katia Raimo; Marco Rossi; Anna Maria Mazzone; Stefano Taddei; Stefano Bombardieri
Journal:  Mol Med       Date:  2009-06-18       Impact factor: 6.354

4.  Protein targets of inflammatory serine proteases and cardiovascular disease.

Authors:  Ram Sharony; Pey-Jen Yu; Joy Park; Aubrey C Galloway; Paolo Mignatti; Giuseppe Pintucci
Journal:  J Inflamm (Lond)       Date:  2010-08-30       Impact factor: 4.981

5.  Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis.

Authors:  Johan M Lorenzen; Celina Schauerte; Anika Hübner; Malte Kölling; Filippo Martino; Kristian Scherf; Sandor Batkai; Karina Zimmer; Ariana Foinquinos; Tamas Kaucsar; Jan Fiedler; Regalla Kumarswamy; Claudia Bang; Dorothee Hartmann; Shashi K Gupta; Jan Kielstein; Andreas Jungmann; Hugo A Katus; Frank Weidemann; Oliver J Müller; Hermann Haller; Thomas Thum
Journal:  Eur Heart J       Date:  2015-04-21       Impact factor: 29.983

6.  Serum osteopontin level correlates with carotid-femoral pulse wave velocity in geriatric persons.

Authors:  Chung-Jen Lee; Ji-Hung Wang; Yu-Chih Chen; Mei-Ling Chen; Chiu-Fen Yang; Bang-Gee Hsu
Journal:  Biomed Res Int       Date:  2014-07-15       Impact factor: 3.411

7.  Utility of Tissue Inhibitor Metalloproteinase-1 and Osteopontin as Prospective Biomarkers of Early Cardiovascular Complications in Type 2 Diabetes.

Authors:  Doaa Samir Salah El-Din; Ahmed Ibrahim Amin; Ahmed Osman Egiza
Journal:  Open Access Maced J Med Sci       Date:  2018-02-10

8.  Association of serum levels of osteopontin and osteoprotegerin with adverse outcomes after endovascular revascularisation in peripheral artery disease.

Authors:  Nikolaos P E Kadoglou; Dimitrios Kapetanios; Emmanouil Korakas; Georgia Valsami; Nikolaos Tentolouris; Nikolaos Papanas; Vaia Lambadiari; Christos Karkos
Journal:  Cardiovasc Diabetol       Date:  2022-09-01       Impact factor: 8.949
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.